natgillin/translations-raw huggingface dataset:
patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis (see section 5.1) patients with relapsing multiple sclerosis.
bolnikov z enim dogodkom demielinizacije z aktivnim vnetnim procesom, če so bile alternativne diagnoze izključene in če je bilo ugotovljeno, da so izpostavljeni visokemu tveganju za razvoj klinično dokončne multiple skleroze (glejte poglavje 5.1) bolnikov z multiplo sklerozo z zagoni.
Patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis (see section 5.1).
bolnikov z enkratnim demielinizacijskim dogodkom, z aktivnim vnetnim procesom, če je dovolj resen, da je potrebno intravensko zdravljenje s kortikosteroidi, če je bila alternativna diagnoza izključena in če je ugotovljeno, da je tveganje za razvoj klinično dokončne multiple skleroze veliko (glejte poglavje 5.1);
Patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis (see section 5.1).
bolnikov, ki so doživeli en demielinizacijski napad z aktivnim vnetnim procesom, če je bil dovolj resen, da upravičuje zdravljenje z intravenoznimi kortikosteroidi, če so bile druge možne diagnoze izključene in če je bolnik uvrščen v visoko stopnjo tveganja, da se bo pri njem/njej razvila klinično jasna multipla skleroza (glejte poglavje 5.1).
patients with a specific cancer of the bone marrow (multiple myeloma) and lack of antibody production with recurrent infections who have failed to respond to a vaccine against certain bacteria (pneumococci). patients with low antibody production prior and after transplantation of bone marrow cells from another person.
bolniki s posebnim rakom kostnega mozga (multiplim mielomom) in pomanjkanjem tvorbe protiteles s ponavljajočimi se okužbami, ki se niso odzvali na cepivo proti določenim bakterijam (pnevmokokom), bolniki z nizko tvorbo protiteles pred presaditvijo celic kostnega mozga druge osebe in po presaditvi.
Patients with a treatment history of immunosuppressant medications are at increased risk for PML.
Pri bolnikih, ki so v preteklosti jemali imunosupresive, je tveganje za PML večje.
Patients with a weakened immune system (immunocompromised patients) treated with IMLYGIC and suffering from concomitant infection
Bolniki z oslabljenim imunskim sistemom (imunokompromitirani bolniki), ki so zdravljeni z zdravilom IMLYGIC, in imajo sočasno okužbo.
Patients with ACR20 15/88
bolniki z odzivom ACR 20/
Patients with ACR20 response/ Patients evaluated (%)
bolniki z odzivom ACR 20/ pregledani bolniki (%)c
Patients with active autoimmune disease, ocular melanoma or a known history of prior ipilimumab-related high-grade (Grade 4 per CTCAE v4.0) adverse reactions, except for resolved nausea, fatigue, infusion reactions, or endocrinopathies, were excluded from the study.
Bolnike z aktivno avtoimunsko boleznijo, očesnim melanomom ali znanimi neželenimi učinki visoke stopnje (stopnja 4 po CTCAE v4.0) pri predhodnem zdravljenju z ipilimumabom, razen navzee, utrujenosti, infuzijskih reakcij ali endokrinopatij, ki so izzvenele, so iz študije izključili.
Patients with active hepatitis B disease should not be treated with MabThera.
Bolniki z aktivno boleznijo, povzročeno z virusom hepatitisa B, se ne smejo zdraviti z zdravilom MabThera.
Patients with active infection should be treated for the underlying condition prior to receiving therapy with cladribine.
Bolnike z aktivno okužbo je treba pred prejemanjem zdravljenja s kladiribinom zdraviti za predhodno okužbo.
patients with active polyarticular juvenile idiopathic arthritis from 2 years of age and active enthesitis-related arthritis from 6 years of age (both are rare diseases causing inflammation in the joints);
bolnikov, starejših od dveh let, z aktivnim poliartikularnim juvenilnim idiopatskim artritisom in bolnikov, starejših od šest let, z artritisom, povezanim z entezitisom (obe bolezni sta redki in povzročata vnetje sklepov);
Patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or patients having acute respiratory failure.
Bolniki z akutno kritično boleznijo zaradi zapletov po operaciji na odprtem srcu ali operaciji trebuha, bolniki z mnogovrstnimi nezgodnimi poškodbami ali bolniki z akutno respiratorno odpovedjo.
patients with acute infections.
bolnikov z akutno okužbo,
Patients with adrenal insufficiency should be monitored for thyroid dysfunction as both hypothyroidism and hyperthyroidism may markedly influence the exposure of administered hydrocortisone.
Pri bolnikih z adrenalno insuficienco je treba spremljati delovanje ščitnice, saj lahko hipotiroidizem in hipertiroidizem pomembno vplivata na izpostavljenost uporabljenemu hidrokortizonu.
Patients with adult respiratory distress syndrome, endocarditis, prosthetic heart valves, systemic inflammation, sepsis, hyperactive coagulation and/or recurrent thromboembolism
Bolniki s sindromom dihalne stiske pri odraslem, z endokarditisom, z umetnimi srčnimi zaklopkami, sistemskim vnetjem, sepso, hiperkoagulacijo in/ali ponavljajočo se trombembolijo
Patients with advanced HIV disease may be at risk of elevated triglycerides and pancreatitis
Bolnike z napredovalo boleznijo HIV utegneta ogrožati zvišanje trigliceridov in pankreatitis.
Patients with advanced Parkinson’s disease
Bolniki z napredovalo Parkinsonovo boleznijo
Patients with advanced renal disease
Bolniki z napredovalo ledvično boleznijo
patients with alcoholism.
bolnikih, ki trpijo za alkoholizmom.
Patients with all degrees of hepatic impairment may have tachycardia or hypotension for 30-60 minutes after Ceplene+IL-2 administration.
Pri bolnikih z različnimi stopnjami jetrnih okvar se lahko za 30–60 minut po uporabi zdravila Ceplene+IL-2 pojavi tahikardija ali hipotenzija.
patients with allergic predisposition
bolnikih z nagnjenjem do alergij;
Patients with allergy to gluten or diabetics should take notice that one tablet of Velphoro is equivalent to 0.116 bread units (equivalent to approximately 1.4 g of carbohydrates).
Bolniki z alergijo na gluten ali diabetiki morajo upoštevati, da ena tableta zdravila Velphoro ustreza 0,116 krušne enote (enako kot približno 1,4 g ogljikovih hidratov).
Patients with ALT Elevation/ Patients with Observations*
Bolniki s povišanimi vrednostmi ALT / opazovani bolniki
Patients with ALT Elevation/ Patients with Observations*
Bolniki z zvišano aktivnostjo ALT/ Opazovani bolniki
Patients with ALT or AST > 2 times the ULN prior to treatment were not included in clinical studies; treatment initiation is not recommended in patients with ALT or AST > 2 times the ULN.
Bolniki z ALT ali AST > 2-kratna ULN pred zdravljenjem niso bili vključeni v klinične študije; uvedba zdravljenja se pri bolnikih z ALT ali AST > 2-kratna ULN ne priporoča.
Patients with Alzheimer’s disease may lose weight whilst taking cholinesterase inhibitors, including rivastigmine.
Bolniki z Alzheimerjevo boleznijo lahko hujšajo v času jemanja zaviralcev holinesteraze, tudi rivastigmina.
Patients with Alzheimer’s disease may lose weight.
Bolniki z Alzheimerjevo boleznijo včasih hujšajo.
patients with an active infection at the surgery site;
pri bolnikih z aktivno okužbo na mestu kirurškega posega;
patients with an auto-immune disease (a disease caused by the body’s own defence system attacking normal tissue);
bolnikih z avtoimunsko boleznijo (boleznijo bolnikovega lastnega obrambnega sistema, ki napada normalno tkivo),
patients with an inadequate blood supply at the fracture site;
pri bolnikih, ki na mestu zloma nimajo ustrezne prekrvavitve;
patients with an inborn inability or reduced ability to produce antibodies (primary immunodeficiencies).
bolniki s prirojeno nezmožnostjo ali zmanjšano zmožnostjo tvorbe protiteles (primarno imunsko pomanjkljivostjo),
Patients with and without cardiovascular risk factors, including patients age 50 years or younger, experienced these events.
Ta dogodek se je pojavil pri bolnikih z dejavniki kardiovaskularnega tveganja in brez njih, vključno z bolniki, starimi 50 let ali manj.
Patients with angioedema have attacks of swelling that can occur anywhere in the body, such as in the face or limbs, or around the gut, causing discomfort and pain.
Bolniki z angioedemom imajo napade otekanja, ki se lahko pojavijo kjer koli na telesu, kot na primer na obrazu ali okončinah ali v predelu trebuha, kar povzroča neugodje in bolečino.
Patients with angioedema should be managed according to standard of care.
Bolnike z angioedemom je treba obravnavati v skladu s standardno nego.
Patients with antibodies to r-hαGAL have a greater potential to experience infusion-associated reactions (IARs).
Bolniki s protitelesi proti r-hαGAL imajo večjo možnost pojava reakcij, povezanih z infuzijo.
Patients with any active pathological bleeding (see sections 4.4 and 4.8).
bolniki s kakršno koli aktivno patološko krvavitvijo (glejte poglavji 4.4 in 4.8),
Patients with any clinical worsening
bolniki s kakršnim koli kliničnim poslabšanjem
Patients with any history of or concurrent brain metastases, active autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the pivotal trial in RCC (see sections 4.5 and 5.1).
Bolnike z anamnezo zasevkov v možganih ali s trenutnimi zasevki v možganih, z aktivno avtoimunsko boleznijo ali zdravstvenimi stanji, ki so zahtevala sistemsko imunosupresivno zdravljenje, so iz ključnega preskušanja pri RCC izključili (glejte poglavji 4.5 in 5.1).
Patients with any history of or concurrent brain metastases, prior treatment with an mammalian target of rapamycin (mTOR) inhibitor, active autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the study.
Bolnike z anamnezo zasevkov v možganih ali s trenutnimi zasevki v možganih, predhodnim zdravljenjem z zaviralcem mTOR (tarče rapamicina pri sesalcih; mammalian target of rapamycin), aktivno avtoimunsko boleznijo ali zdravstvenimi stanji, ki so zahtevala zdravljenje s sistemsko imunosupresijo, so iz te študije izključili.
Patients with any known history of drug allergy including hypersensitivity to other parenteral iron products
bolnikih s katero koli znano alergijo na zdravila v preteklosti, vključno s preobčutljivostjo na druga parenteralna zdravila, ki vsebujejo železo
Patients with any transfusion
Bolniki brez vsakršne transfuzije
Patients with asthma: The population pharmacokinetics of omalizumab were analysed to evaluate the effects of demographic characteristics.
Bolniki z astmo: Analizirali so populacijsko farmakokinetiko omalizumaba, da bi ovrednotili učinke demografskih značilnosti.
patients with auto-immune hepatitis (when the body’s natural defences attack the liver);
bolnikih z avtoimunskim hepatitisom (kadar naravni obrambni mehanizem telesa napada jetra);
Patients with autoimmune hepatitis.
Bolniki z avtoimunskim hepatitisom.
Patients with axial spondyloarthritis should receive either 200 mg every two weeks or 400 mg every four weeks.
Bolniki z aksialnim spondiloartritisom prejmejo bodisi 200-miligramski odmerek vsaka dva tedna bodisi 400-miligramski odmerek vsake štiri tedne.
Patients with baseline elevation of ALT (e.g. due to liver metastases) may be predisposed to liver injury with a higher risk of a Grade 3-5 hepatic event or liver function test increase.
Bolniki z izhodiščnim zvišanjem ALT (npr. zaradi jetrnih metastaz) imajo lahko večje tveganje za poškodbo jeter z večjim tveganjem za jetrne neželene dogodke stopnje 3 do 5 ali zvišanje jetrnih testov.
Patients with baseline HbA1c > 10% to ≤ 12%
Bolniki z izhodiščno ravnijo HbA1c od > 10% do ≤ 12
Patients with baseline HbA1c ≥ 9%
Bolniki z izhodiščnim HbA1c ≥ 9
Patients with baseline HbA1c ≥ 9%
Bolniki z izhodiščno vrednostjo HbA1c ≥ 9
Patients with baseline HbA1c ≥9%
Bolniki z izhodiščno vrednostjo HbA1c ≥ 9
Patients with baseline neutrophil counts of <1.5 x 109/L and/or thrombocyte counts of
Bolnikov, ki imajo pred zdravljenjem število nevtrofilcev < 1,5 x 109/l in/ali število trombocitov
Patients with baseline renal impairment had a higher incidence of Grade 3 or 4 hypertension, proteinuria, fatigue, stomatitis, oedema peripheral, thrombocytopenia, dehydration, prolonged electrocardiogram QT, hypothyroidism, hyponatraemia, blood thyroid stimulating hormone increased, pneumonia compared with subjects with normal renal function.
Bolniki z izhodiščno okvaro ledvic so imeli večjo incidenco hipertenzije, proteinurije, utrujenosti, stomatitisa, perifernih edemov, trombocitopenije, dehidracije, podaljšanega intervala QT v elektrokardiogramu, hipotiroidizma, hiponatriemije, zvišanega tirotropnega hormona v krvi in pljučnice stopnje 3 ali 4 v primerjavi s preiskovanci z normalno funkcijo ledvic.
Patients with BCR-ABL > 10% at 3 months
BCR-ABL > 10% v 3. mesecu
Patients with BCR-ABL ≤ 10% at 3 months
≤ 10% v 3. mesecu
Patients with benefit/patients with abnormality at baseline (%)
Bolniki z doseženo koristjo/bolniki z izhodiščno nepravilnostjo (%)
Patients with bladder outlet obstruction and patients taking antimuscarinics medications for OAB
Bolniki z obstrukcijo sečnega mehurja in bolniki, ki jemljejo antimuskarinike za zdravljenje PASM
Patients with bleeding (WHO Grades 1-4) at any time during 6 months, n (%) p-value a
Bolniki s krvavitvami (stopnje 1-4 po SZO) v kateremkoli času med 6 mesečnim obdobjem, n (%)
Patients with bleeding (WHO Grades 2-4) at any time during 6 months, n (%) p-value a
Bolniki s krvavitvami (Stopnje 2-4 po SZO) v kateremkoli času med 6 mesečnim obdobjem, n (%) vrednost pa
Patients with blood cancer (chronic lymphocytic leukaemia) who have low immunoglobulin levels in the blood (hypogammaglobulinaemia) and develop recurrent infections and for whom preventative antibiotics have failed.
Bolniki s krvnim rakom (kronična limfocitna levkemija), ki imajo nizke ravni imunoglobulina v krvi (hipogamaglobulinemija) in pri katerih se sočasno razvije okužba, in pri katerih preventiva z antibiotiki ni uspešna.
Patients with blood cancers can switch to an injection given under the skin after they have received one full dose of the infusion.
Bolniki s krvnimi raki lahko preidejo na injiciranje v podkožje, ko prejmejo en celoten odmerek v obliki infuzije.
Patients with BMI > 30 kg/m2
Bolniki z ITM> 30 kg/m2
Patients with body weight <60 kg
Bolniki s telesno maso <60 kg
Patients with body weight below 50 kg may experience more adverse reactions and may be more likely to discontinue due to adverse reactions (see section 4.2).
Pri bolnikih s telesno maso manjšo od 50 kg je lahko število neželenih učinkov večje, obstaja pa tudi večja verjetnost, da bodo zaradi neželenih učinkov zdravljenje prekinili (glejte poglavje 4.2).
Patients with body weight below 50 kg: Particular caution should be exercised in titrating patients with body weight below 50 kg above the recommended effective dose of 9.5 mg/24 h (see section 4.4).
Bolniki s telesno maso manjšo od 50 kg: Pri bolnikih s telesno maso manjšo od 50 kg je pri zviševanju odmerka nad priporočeni učinkoviti odmerek 9,5 mg/24 h potrebna posebna previdnost (glejte poglavje 4.4).
Patients with body weight greater than or equal to 80 kg
Bolniki s telesno maso 80 kg ali več
Patients with bodyweight greater than 100 kg
Bolniki s telesno maso več kot 100 kg
Patients with bone marrow cancer (multiple myeloma) who have low immunoglobulin levels in the blood and develop recurrent infections, if no immune response is obtained after vaccination against certain bacteria (pneumococci).
Bolniki z rakom kostnega mozga (multipli mielom), ki imajo nizke ravni imunoglobulina v krvi in pri katerih se sočasno razvije okužba, če po cepljenju proti nekaterih bakterijam (pnevmokokom) ni ustreznega imunskega odziva.
Patients with both CIRS > 6 and CrCl < 70 mL/min are more at risk of infections, including severe infections (see section 4.8).
Bolniki, ki imajo hkrati CIRS > 6 in očistek kreatinina < 70 ml/min, imajo večje tveganje za okužbe, vključno s hudimi okužbami (glejte poglavje 4.8).
Patients with brain metastases (Results from the Phase II study (BREAK-MB)
Bolniki z metastazami na možganih (rezultati študije II. faze [BREAK-MB])
patients with bronchial asthma; in these patients it is especially the risk of bronchospasm which is increased patients with a history of reactions to contrast agents, including a previous history of reaction to iodine-based contrast agents
bolnikih z bronhialno astmo; pri teh bolnikih je zlasti povečano tveganje za pojav bronhospazmov; bolnikih z reakcijami na kontrastna sredstva v anamnezi, vključno z reakcijami na kontrastna sredstva na osnovi joda.
Patients with cancer
Bolniki, oboleli za rakom
Patients with cancer of the bone marrow (multiple myeloma) and lack of antibody production with recurrent infections who have failed to respond to a vaccine against certain bacteria (pneumococci).
Bolniki z rakom kostnega mozga (multiplim mielomom) ter prenehanjem nastajanja protiteles in ponavljajočimi se okužbami, ki jih ne prepreči cepljenje proti določenim bakterijam (pnevmokokom).
patients with cancer or being treated for cancer;
bolnikih z rakom ali bolniki, ki se zdravijo zaradi raka;
Patients with cancer should continue to receive treatment for up to four weeks after they stop receiving chemotherapy.
Bolniki z rakom naj zdravljenje nadaljujejo do štiri tedne po prenehanju zdravljenja s kemoterapijo.
Patients with cancer-related pain
Bolniki z bolečinami zaradi raka
Patients with Candida endocarditis, osteomyelitis or meningitis, or those with infection due to C. krusei, were specifically excluded from the study.
Iz študije so bili specifično izključeni bolniki, ki so imeli endokarditis, osteomielitis ali meningitis, povzročen s Candido, in bolniki, ki so imeli okužbo s C. krusei.
Patients with CAPS and Still’s disease (or their carers) may inject Ilaris once they have been trained if their doctor believes it is appropriate.
Bolniki z obolenji CAPS in Stillovo boleznijo (ali njihovi negovalci) lahko zdravilo Ilaris injicirajo sami, če so o tem ustrezno poučeni in če njihov zdravnik oceni, da je to primerno.
Patients with cardiac arrhythmias
pri bolnikih s srčnimi aritmijami,
Patients with cardiac impairment
Bolniki z okvaro srca
Patients with Cardiac Shunts
Bolniki s srčnimi spoji (šanti)
Patients with cardiovascular co-morbidities could be at increased risk of cardiovascular adverse events triggered by postural hypotension.
Bolniki s sočasnimi kardiovaskularnimi boleznimi imajo lahko večje tveganje za neželene kardiovsakularne učinke, ki jih izzove posturalna hipotenzija.
Patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal's angina and cardiac failure) and hypotension therapy with beta-blockers should be critically assessed and therapy with other active substances should be considered.
Bolnike s srčnožilnimi boleznimi (npr. koronarno srčno boleznijo, Prinzmetalovo angino in srčnim popuščanjem) in bolnike na zdravljenju hipotenzije z antagonisti adrenergičnih receptorjev beta je treba kritično oceniti in razmisliti o zdravljenju z drugimi zdravilnimi učinkovinami.
Patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal's angina and cardiac failure) and receiving hypotension therapy with beta-blockers should be critically assessed and therapy with other active substances should be considered.
Bolnike s srčnožilnimi boleznimi (npr. koronarno srčno boleznijo, Prinzmetalovo angino in srčnim popuščanjem) in bolnike, ki prejemajo za zdravljenje hipotenzije antagoniste adrenergičnih receptorjev beta, je treba kritično oceniti in razmisliti o zdravljenju z drugimi zdravilnimi učinkovinami.
Patients with CHF showed a higher overall incidence of hypotensive events, during the first 2 hours after dose in patients treated with vernakalant compared to patients receiving placebo (16.1% versus 4.7%, respectively).
Pri bolnikih s kongestivnim srčnim popuščanjem je bila celotna pojavnost hipotenzivnih dogodkov v prvih 2 urah po odmerku zdravila večja med bolniki, ki so prejeli vernakalant (16,1 %), kot med bolniki, ki so prejeli placebo (4,7 %).
Patients with chronic diarrhoea or malabsorption: No information on boosted saquinavir and only limited information on the safety and efficacy of unboosted saquinavir is available for patients suffering from chronic diarrhoea or malabsorption.
Bolniki s kronično diarejo ali malabsorpcijo: za bolnike s kronično diarejo ali malabsorpcijo so na voljo le omejeni podatki o varnosti in učinkovitosti sakvinavirja brez podporne terapije, za sakvinavir s podporno terapijo pa podatkov ni.
Patients with chronic disease conditions 21 Days After
21 dni po 21 dni po
Patients with chronic hepatitis B or C and treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Pri bolnikih s kronično okužbo z virusom hepatitisa B ali C, ki se zdravijo s protiretrovirusnimi zdravili, obstaja večje tveganje za hude in morebitno smrtne neželene učinke na jetrih.
Patients with chronic hepatitis B or C and treated with CART are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Pri bolnikih s kroničnim hepatitisom B ali C, ki prejemajo zdravljenje CART, je tveganje za hude in potencialno smrtne neželene učinke v jetrih povečano.
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Za bolnike s stabilno hudo okvaro jeter (razred C po Child-Pughu) brez dekompenzacije glejte poglavje 4.2. Bolnike s kroničnim hepatitisom B ali C, ki dobivajo kombinirano protiretrovirusno terapijo, bolj ogrožajo hudi in potencialno smrtni neželeni učinki na jetrih.
Patients with chronic hepatitis B or C treated with ART are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Pri bolnikih s kroničnim hepatitisom B ali C, zdravljenih s protiretrovirusnimi zdravili, obstaja večje tveganje za resne in potencialno smrtne neželene učinke na jetra.
Patients with chronic kidney disease are predisposed to developing metabolic acidosis.
Bolniki s kronično ledvično boleznijo so nagnjeni k razvoju metabolične acidoze.
Patients with chronic kidney problems
Pacienti s kroničnimi ledvičnimi težavami
Patients with chronic obstructive pulmonary disease (COPD), or who are heavy smokers, may be at increased risk for cancer with Cimzia treatment.
Bolniki s kronično obstruktivno pljučno boleznijo (KOPB) ali bolniki, ki so hudi kadilci, so med zdravljenjem z zdravilom Cimzia lahko izpostavljeni povečanemu tveganju za nastanek raka.
Patients with chronic renal failure, patients with creatinine clearance < 50 ml/minute and/or on haemodialysis.
Bolniki s kronično ledvično odpovedjo, bolniki z očistkom kreatinina < 50 ml/min in/ali hemodializo;
Patients with chronic renal impairment on CRRT can be treated with either a 1 or 4-hour infusion time.
Pri bolnikih s kronično ledvično odpovedjo na CRRT je lahko čas infundiranja 1 ali 4 ure.
Patients with chronic wide-angle glaucoma may be treated with Corbilta with caution, provided the intra-ocular pressure is well controlled and the patient is monitored carefully for changes in intra-ocular pressure.
Bolniki s kroničnim glavkomom odprtega zakotja se ob primerni previdnosti lahko zdravijo z zdravilom Corbilta, pod pogojem, da je intraokularni tlak dobro obvladovan in da bolnika skrbno spremljamo, če bi se pojavile spremembe v intraokularnem tlaku.